FLASCO

 

Corporate Members

Diamond Elite

Diamond

Platinum

Gold

Silver

Latest News

XTANDI Significantly Extended Metastasis-Free Survival in Patients with Nonmetastatic CRPC

Astellas Pharma US, Inc. and Pfizer Inc. are pleased to announce that XTANDI is now indicated for the treatment of patients with CRPC.1 PROSPER was a multinational, randomized, double-blind, placebo-controlled phase 3 study of XTANDI + LHRH therapy† in patients with nonmetastatic CRPC who had progressed on LHRH therapy.†1,2 In PROSPER, 1401 patients with nonmetastatic...

FDA expands ribociclib indication in HR-positive, HER2-negative advanced or metastatic breast cancer

On July 18, 2018, the Food and Drug Administration expanded the indication for ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) in combination with an aromatase inhibitor for pre/perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. FDA also approved ribociclib in combination with fulvestrant for postmenopausal women with HR-positive, HER2-negative advanced or...

FLASCO Donates $20,000 to Provide Scholarships for University of Puerto Rico School of Medicine First Year Students for a Summer Research Fellowship in Cancer Research at Mayo Clinic Cancer Center Jacksonville, Fl in Summer 2018. 

FLASCO donated $20,000 to provide 4 scholarships for University of Puerto Rico School of Medicine First Year Students a Summer Research Fellowship in Cancer Research at Mayo Clinic Cancer Center Jacksonville, Fl in Summer 2018. This program, originally funded by the NIH CCATS grant, consists of a week long course on research given by faculty...

FDA Approves enzalutamide for castration-resistant prostate cancer

On July 13, 2018, the Food and Drug Administration approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). This approval broadens the indicated patient population to include patients with both non-metastatic CRPC (NM-CRPC) and metastatic CRPC. Enzalutamide was previously approved for the treatment of patients with metastatic CRPC. Approval in...

FDA grants accelerated approval to ipilimumab for MSI-H or dMMR metastatic colorectal cancer

On July 10, 2018, the Food and Drug Administration granted accelerated approval to ipilimumab (YERVOY®, Bristol-Myers Squibb Company Inc.) for use in combination with nivolumab for the treatment of patients 12 years of age and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with...

Who’s Online

There are no users currently online